Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

BioNova Pharmaceuticals

    • Home
    • BioNova Pharmaceuticals
Company Deals

Servier Acquires BioNova’s BN104 for Acute Leukemia Treatment

Fineline Cube May 23, 2025

French pharmaceutical firm Servier announced a definitive agreement to acquire BN104 from BioNova Pharmaceuticals (Shanghai)...

Company Drug

BioNova Pharmaceuticals’ BN104 Receives Breakthrough Therapy Designation in China

Fineline Cube Dec 18, 2024

The China’s Center for Drug Evaluation (CDE) website has indicated that BioNova Pharmaceuticals (Shanghai) Ltd.’s...

Company Deals Drug

Sanofi Regains Exclusive Rights to Rezurock in China, Terminating Agreement with BioNova and BK Pharmaceuticals

Fineline Cube Nov 3, 2023

BioNova Pharmaceuticals, a Shanghai-based oncology-focused biopharmaceutical company founded in 2018, and Sanofi (NASDAQ: SNY), a...

Recent updates

  • Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma
  • European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance
  • CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline
  • Keymed Biosciences Secures NMPA Breakthrough Therapy Designation for CM336 in AL Amyloidosis
  • Innovent Biologics Secures Third Breakthrough Therapy Designation for IBI363 in MSS/pMMR Colorectal Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma

Company Drug

European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance

Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Company Drug

Keymed Biosciences Secures NMPA Breakthrough Therapy Designation for CM336 in AL Amyloidosis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.